D. E. Shaw & Co., Inc. Uni Qure N.V. Transaction History
D. E. Shaw & Co., Inc.
- $114 Billion
- Q1 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Uni Qure N.V. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 850,100 shares of QURE stock, worth $3.26 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
850,100
Previous 560,331
51.71%
Holding current value
$3.26 Million
Previous $3.79 Million
16.53%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding QURE
# of Institutions
148Shares Held
34.1MCall Options Held
1.07MPut Options Held
603K-
Vestal Point Capital, LP New York, NY4.73MShares$18.1 Million2.03% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.09MShares$11.9 Million1.03% of portfolio
-
683 Capital Management, LLC New York, NY1.98MShares$7.58 Million0.88% of portfolio
-
Black Rock Inc. New York, NY1.86MShares$7.15 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.52MShares$5.83 Million0.0% of portfolio
About uniQure N.V.
- Ticker QURE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,729,100
- Market Cap $179M
- Description
- uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...